X-Linked Agammaglobulinemia: Infection Frequency and Infection-Related Mortality in the USIDNET Registry.

Area of Science:

• Immunology
• Genetics
• Pediatrics

Background:

• X-linked agammaglobulinemia (XLA) is a primary immunodeficiency caused by BTK gene mutations, leading to B cell deficiency and increased infection susceptibility.
• The impact of early diagnosis and treatment on XLA morbidity and mortality remains incompletely understood.

Purpose of the Study:

• To investigate the relationship between age at diagnosis and treatment initiation and infection frequency and infection-related mortality in XLA patients.
• To determine if earlier intervention in XLA can mitigate disease severity and improve outcomes.

Main Methods:

• Analysis of data from 231 XLA patients in the USIDNET Registry.
• Examining infection frequency, infection-related mortality, and their correlation with age of diagnosis and treatment initiation.

Main Results:

• Respiratory infections were reported in 88% of XLA patients, and infection was the cause of death in 71% of deceased patients with known causes.
• Earlier diagnosis (median 1.5 years) and treatment initiation (median 1.0 year) were associated with fewer lower respiratory tract infections (LRTIs).
• Each year increase in age at therapy start increased LRTI odds by 1.216 (OR 1.216, 95% CI 1.048-1.411, p=0.01).

Conclusions:

• Earlier diagnosis and treatment initiation in XLA are linked to reduced frequency of severe respiratory infections and improved survival.
• The study strongly supports the inclusion of XLA in newborn screening programs to enable prompt diagnosis and management.